CytomX Therapeutics CTMX Other Wholly Owned And Partnered Programs — Total External Costs
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by CytomX Therapeutics in its filing.
Tagged under the XBRL concept ctmx:TotalExternalCosts.
The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about CytomX Therapeutics's other wholly owned and partnered programs — total external costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CytomX Therapeutics's other wholly owned and partnered programs — total external costs?
- CytomX Therapeutics (CTMX) reported other wholly owned and partnered programs — total external costs of $143K in Q1 2026.
- How has CytomX Therapeutics's other wholly owned and partnered programs — total external costs changed year-over-year?
- CytomX Therapeutics's other wholly owned and partnered programs — total external costs decreased by 64.0% year-over-year, from $397K to $143K.
- What is the long-term trend for CytomX Therapeutics's other wholly owned and partnered programs — total external costs?
- Over 2 years (2023 to 2025), CytomX Therapeutics's other wholly owned and partnered programs — total external costs has grown at a -45.6% compound annual growth rate (CAGR), from $6.49M to $1.92M.
- What does other wholly owned and partnered programs — total external costs mean?
- This metric represents the aggregate third-party expenditures, including contract research organization fees and clinical trial costs, directly attributable to the company's secondary portfolio of wholly owned and partnered therapeutic programs. It serves as a key indicator of the capital intensity and R&D investment level required to advance these specific drug candidates through the development pipeline. Monitoring these costs helps investors assess the efficiency of resource allocation across the company's non-core or early-stage development assets.